SFM
TEVA icon

Sphera Funds Management’s Teva Pharmaceuticals TEVA Stock Holding History

Sphera Funds Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$34.2M Buy
1,136,975
+13,450
+1% +$433K 5.44% 2
2025
Q4 		$35.1M Sell
1,123,525
-383,500
-25% -$9.45M 6.78% 1
2025
Q3 		$30.4M Sell
1,507,025
-113,965
-7% -$2M 6.42% 1
2025
Q2 		$27.2M Buy
1,620,990
+48,809
+3% +$788K 6.38% 1
2025
Q1 		$24.2M Buy
1,572,181
+3,000
+0.2% +$53.6K 5.56% 1
2024
Q4 		$34.6M Sell
1,569,181
-561,035
-26% -$10.2M 6.25% 1
2024
Q3 		$38.4M Buy
2,130,216
+1,340,800
+170% +$23.5M 6.11% 1
2024
Q2 		$12.8M Sell
789,416
-1,100,284
-58% -$16.9M 1.75% 14
2024
Q1 		$26.7M Sell
1,889,700
-579,400
-23% -$7.3M 3.75% 3
2023
Q4 		$25.8M Buy
2,469,100
+1,869,100
+312% +$17.5M 4.15% 2
2023
Q3 		$6.12M Sell
600,000
-450,000
-43% -$4.19M 1.11% 32
2023
Q2 		$7.91M Sell
1,050,000
-989,500
-49% -$8.02M 1.23% 22
2023
Q1 		$18M Buy
+2,039,500
New +$20.2M 3.02% 7
2022
Q4 		– Sell
-776,346
Closed -$6.77M – 84
2022
Q3 		$6.26M Sell
776,346
-371,532
-32% -$3.29M 0.87% 40
2022
Q2 		$8.63M Buy
1,147,878
+315,000
+38% +$2.74M 0.92% 25
2022
Q1 		$7.82M Buy
832,878
+1
+0% +$8 1.11% 27
2021
Q4 		$6.67M Sell
832,877
-1
-0% -$9 0.73% 47
2021
Q3 		$8.11M Hold
832,878
– – 0.68% 47
2021
Q2 		$8.24M Hold
832,878
– – 0.56% 49
2021
Q1 		$9.61M Hold
832,878
– – 0.74% 33
2020
Q4 		$8.04M Sell
832,878
-750,000
-47% -$7.18M 0.71% 45
2020
Q3 		$14.3M Buy
1,582,878
+1,000,000
+172% +$10.6M 1.4% 17
2020
Q2 		$7.19M Buy
582,878
+226,165
+63% +$2.56M 0.68% 39
2020
Q1 		$3.2M Buy
356,713
+96,361
+37% +$987K 0.4% 44
2019
Q4 		$2.55M Buy
+260,352
New +$2.32M 0.21% 70
2019
Q3 		– Sell
-793,834
Closed -$6.08M – 100
2019
Q2 		$7.33M Buy
793,834
+740,000
+1,375% +$8.92M 1% 28
2019
Q1 		$844K Sell
53,834
-650,666
-92% -$11.5M 0.08% 95
2018
Q4 		$10.9M Buy
704,500
+504,500
+252% +$10.3M 1.22% 21
2018
Q3 		$4.31M Buy
+200,000
New +$4.64M 0.49% 57
2018
Q1 		– Sell
-118,750
Closed -$2.25M – 141
2017
Q4 		$2.25M Sell
118,750
-281,250
-70% -$4.23M 0.26% 87
2017
Q3 		$7.04M Buy
+400,000
New +$9M 1% 21
2017
Q2 		– Sell
-172,000
Closed -$5.32M – 139
2017
Q1 		$5.52M Sell
172,000
-350,000
-67% -$11.9M 1.08% 22
2016
Q4 		$18.9M Buy
522,000
+120,000
+30% +$4.79M 4.79% 4
2016
Q3 		$18.5M Sell
402,000
-198,200
-33% -$10.3M 3.01% 4
2016
Q2 		$30.1M Sell
600,200
-125,000
-17% -$6.65M 7.83% 1
2016
Q1 		$38.8M Sell
725,200
-59,650
-8% -$3.5M 8.41% 3
2015
Q4 		$51.5M Buy
784,850
+31,945
+4% +$1.97M 7.54% 2
2015
Q3 		$42.5M Buy
752,905
+575,605
+325% +$37.3M 5.42% 4
2015
Q2 		$10.5M Sell
177,300
-225,519
-56% -$13.9M 1.03% 17
2015
Q1 		$25.1M Buy
402,819
+6,550
+2% +$381K 2.61% 7
2014
Q4 		$22.8M Sell
396,269
-251,169
-39% -$14M 3.88% 4
2014
Q3 		$34.8M Buy
647,438
+202,938
+46% +$10.8M 4.3% 4
2014
Q2 		$23.3M Buy
444,500
+382,900
+622% +$19.6M 5.74% 3
2014
Q1 		$3.25M Sell
61,600
-88,400
-59% -$4.09M 0.74% 27
2013
Q4 		$6.01M Buy
+150,000
New +$5.91M 1.67% 16

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sphera Funds Management's TEVA Position: Q1 2026 in Review

Sphera Funds Management increased its Teva Pharmaceuticals (TEVA) stake by 1.2% in Q1 2026, buying an estimated $433K and bringing the position to 1,136,975 shares worth $34.2M. The position accounts for 5.44% of the portfolio, ranked #2.

Sphera Funds Management first reported a position in TEVA in Q4 2013 and has held it in 45 quarters since. The position peaked at $51.5M in Q4 2015. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Sphera Funds Management held 1,136,975 shares of Teva Pharmaceuticals worth $34.2M as of Q1 2026.
  • Sphera Funds Management bought 13,450 Teva Pharmaceuticals shares in Q1 2026, an estimated $433K.
  • Teva Pharmaceuticals made up 5.44% of Sphera Funds Management's portfolio in Q1 2026, its #2 holding.
  • Sphera Funds Management first reported a position in Teva Pharmaceuticals in Q4 2013 and has held it in 45 quarters since.
  • Sphera Funds Management's Teva Pharmaceuticals position peaked at $51.5M in Q4 2015.
  • 650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Sphera Funds Management's 13F filing for Q1 2026, filed 15 May 2026.